Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

Pacific Edge upbeat about latest move for new test
Markets

Pacific Edge upbeat about latest move for new test

The median price for Cxbladder Triage Plus is US$1,018.44.

Second Auckland airport runway pushed out to 2038
Infrastructure

Second Auckland airport runway pushed out to 2038

The new draft master plan will be finalised by year-end.

Kernel adds shares and ETFs, but no day trading
Finance

Kernel adds shares and ETFs, but no day trading

Kernel Wealth's test share buyers have been piling into Nvidia, Apple and Google.

NZ sharemarket up as Trump eases tariff stance
Markets Market Close

NZ sharemarket up as Trump eases tariff stance

Investors heaved a sigh of relief as NZ shares responded to Trump's change of heart.

Tom Raynel 28 Apr 2025